These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36248326)

  • 1. Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study.
    Uda S; Yamada T; Yoshimura A; Goto Y; Yoshimine K; Nakamura Y; Shiotsu S; Yokoi T; Tamiya N; Kimura H; Chihara Y; Umeda Y; Izumi M; Takeda T; Yamada T; Hibino M; Hiranuma O; Ito K; Okada A; Osugi S; Takemura Y; Ishii H; Chibana K; Hasegawa I; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
    Transl Lung Cancer Res; 2022 Sep; 11(9):1847-1857. PubMed ID: 36248326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer.
    Kasajima M; Igawa S; Ishihara M; Otani S; Takakura A; Yokoba M; Kubota M; Sasaki J; Katagiri M; Masuda N
    Oncol Lett; 2017 Mar; 13(3):1719-1724. PubMed ID: 28454315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
    Imai H; Nagai Y; Minemura H; Tsuda T; Yamada Y; Wasamoto S; Kishikawa T; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Minato K; Kagamu H
    Invest New Drugs; 2022 Oct; 40(5):1066-1079. PubMed ID: 35749041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
    Tomono H; Taniguchi H; Fukuda M; Ikeda T; Nagashima S; Akagi K; Ono S; Umeyama Y; Shimada M; Gyotoku H; Takemoto S; Hisamatsu Y; Morinaga R; Tagawa R; Ogata R; Dotsu Y; Senju H; Soda H; Nakatomi K; Hayashi F; Sugasaki N; Kinoshita A; Mukae H
    Thorac Cancer; 2023 Oct; 14(28):2890-2894. PubMed ID: 37675546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
    Miura Y; Kaira K; Sakurai R; Sunaga N; Saito R; Hisada T; Yamada M
    Lung Cancer; 2018 Jan; 115():42-48. PubMed ID: 29290260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
    Uematsu S; Kitazono S; Tanaka H; Saito R; Kawashima Y; Ohyanagi F; Tozuka T; Ryosuke T; Sakatani T; Horiike A; Yoshizawa T; Saiki M; Tambo Y; Koyama J; Kanazu M; Kudo K; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
    Thorac Cancer; 2023 Jan; 14(2):168-176. PubMed ID: 36408699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
    Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
    Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
    Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
    Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
    J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
    Igawa S; Otani S; Ryuge S; Fukui T; Nakahara Y; Hiyoshi Y; Ishihara M; Kusuhara S; Harada S; Mitsufuji H; Kubota M; Sasaki J; Masuda N
    Invest New Drugs; 2017 Oct; 35(5):642-648. PubMed ID: 28631097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amrubicin for non-small-cell lung cancer and small-cell lung cancer.
    Kurata T; Okamoto I; Tamura K; Fukuoka M
    Invest New Drugs; 2007 Oct; 25(5):499-504. PubMed ID: 17628745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure.
    Fujita K; Nakao M; Arakawa S; Sone K; Sato H; Muramatsu H
    J Rural Med; 2021 Oct; 16(4):250-255. PubMed ID: 34707735
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer.
    Ogawara D; Fukuda M; Nakamura Y; Kohno S
    Cancer Manag Res; 2010 Aug; 2():191-5. PubMed ID: 21188110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.
    Sakurai R; Kaira K; Miura Y; Sunaga N; Saito R; Oyama T; Hisada T; Yamada M
    Thorac Cancer; 2020 Feb; 11(2):426-435. PubMed ID: 31901017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.
    Kimura T; Kudoh S; Hirata K
    Clin Med Insights Oncol; 2011 Mar; 5():23-34. PubMed ID: 21499556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.
    Ando T; Hosokawa A; Yoshita H; Ueda A; Kajiura S; Mihara H; Nanjo S; Fujinami H; Nishikawa J; Ogawa K; Nakajima T; Imura J; Sugiyama T
    Gastroenterol Res Pract; 2015; 2015():425876. PubMed ID: 26199623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.